I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| microglial cell | 6 studies | 40% ± 24% | |
| hepatocyte | 5 studies | 51% ± 25% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| microglial cell | 6 studies | 40% ± 24% | |
| hepatocyte | 5 studies | 51% ± 25% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 3 studies | 23% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 22825.10 | 226 / 226 | 67% | 44.05 | 271 / 406 |
| brain | 81% | 269.09 | 2137 / 2642 | 81% | 10.93 | 568 / 705 |
| pancreas | 79% | 1171.79 | 258 / 328 | 71% | 2.56 | 126 / 178 |
| ovary | 38% | 21.85 | 68 / 180 | 55% | 1.72 | 238 / 430 |
| lung | 36% | 60.77 | 206 / 578 | 52% | 1.54 | 606 / 1155 |
| lymph node | 0% | 0 | 0 / 0 | 86% | 10.22 | 25 / 29 |
| breast | 26% | 22.44 | 118 / 459 | 60% | 1.89 | 669 / 1118 |
| prostate | 57% | 56.80 | 139 / 245 | 22% | 0.38 | 108 / 502 |
| skin | 11% | 8.68 | 200 / 1809 | 52% | 3.05 | 247 / 472 |
| adrenal gland | 35% | 20.72 | 90 / 258 | 23% | 0.50 | 52 / 230 |
| heart | 57% | 3194.12 | 495 / 861 | 0% | 0 | 0 / 0 |
| kidney | 3% | 1.42 | 3 / 89 | 52% | 2.57 | 468 / 901 |
| uterus | 7% | 5.51 | 12 / 170 | 34% | 0.87 | 155 / 459 |
| stomach | 13% | 10.81 | 46 / 359 | 25% | 0.68 | 71 / 286 |
| thymus | 9% | 4.40 | 62 / 653 | 26% | 0.59 | 156 / 605 |
| intestine | 11% | 6.29 | 104 / 966 | 19% | 1.96 | 99 / 527 |
| bladder | 5% | 1.76 | 1 / 21 | 23% | 0.57 | 115 / 504 |
| tonsil | 0% | 0 | 0 / 0 | 24% | 0.87 | 11 / 45 |
| peripheral blood | 22% | 109.59 | 203 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 21% | 0.46 | 17 / 80 |
| esophagus | 2% | 2.53 | 24 / 1445 | 15% | 0.29 | 27 / 183 |
| adipose | 14% | 12.41 | 170 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 12% | 9.23 | 156 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 7% | 21.81 | 17 / 241 | 0% | 0 | 0 / 0 |
| muscle | 1% | 0.41 | 10 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006366 | Biological process | transcription by RNA polymerase II |
| GO_0050832 | Biological process | defense response to fungus |
| GO_0002262 | Biological process | myeloid cell homeostasis |
| GO_0042116 | Biological process | macrophage activation |
| GO_0010039 | Biological process | response to iron ion |
| GO_0006954 | Biological process | inflammatory response |
| GO_0045779 | Biological process | negative regulation of bone resorption |
| GO_0034755 | Biological process | iron ion transmembrane transport |
| GO_0060586 | Biological process | multicellular organismal-level iron ion homeostasis |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0051649 | Biological process | establishment of localization in cell |
| GO_0043032 | Biological process | positive regulation of macrophage activation |
| GO_0006955 | Biological process | immune response |
| GO_0045732 | Biological process | positive regulation of protein catabolic process |
| GO_0031640 | Biological process | killing of cells of another organism |
| GO_0050728 | Biological process | negative regulation of inflammatory response |
| GO_0006879 | Biological process | intracellular iron ion homeostasis |
| GO_0030163 | Biological process | protein catabolic process |
| GO_0042742 | Biological process | defense response to bacterium |
| GO_0034760 | Biological process | negative regulation of iron ion transmembrane transport |
| GO_1904479 | Biological process | negative regulation of intestinal absorption |
| GO_0007259 | Biological process | cell surface receptor signaling pathway via JAK-STAT |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0005634 | Cellular component | nucleus |
| GO_0005179 | Molecular function | hormone activity |
| GO_0005507 | Molecular function | copper ion binding |
| Gene name | HAMP |
| Protein name | Hepcidin antimicrobial peptide Hepcidin (Liver-expressed antimicrobial peptide 1) (LEAP-1) (Putative liver tumor regressor) (PLTR) [Cleaved into: Hepcidin-25 (Hepc25); Hepcidin-20 (Hepc20)] |
| Synonyms | LEAP1 UNQ487/PRO1003 HEPC |
| Description | FUNCTION: Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues. Acts by promoting endocytosis and degradation of ferroportin/SLC40A1, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma . Controls the major flows of iron into plasma: absorption of dietary iron in the intestine, recycling of iron by macrophages, which phagocytose old erythrocytes and other cells, and mobilization of stored iron from hepatocytes . .; FUNCTION: Has strong antimicrobial activity against E.coli ML35P N.cinerea and weaker against S.epidermidis, S.aureus and group b streptococcus bacteria. Active against the fungus C.albicans. No activity against P.aeruginosa . . |
| Accessions | P81172 Q6KC15 ENST00000598398.5 ENST00000222304.5 B6EU04 |
